```html

Zoster oticus (Ramsay Hunt syndrome)

Overview

Zoster oticus, more commonly known as Ramsay Hunt syndrome (RHS), is a neurological disorder caused by the reactivation of the varicella‑zoster virus (VZV) in the facial (VII) nerve, often involving the vestibulocochlear (VIII) nerve. The condition is characterized by a painful rash around the ear or on the oral mucosa accompanied by facial paralysis, hearing loss, and vertigo.

• Typical age group: Adults 40–70 years, but it can occur at any age, including children.
• Sex distribution: Slight male predominance (≈55 % men).
• Prevalence: RHS accounts for about 5–12 % of all facial nerve palsies. In the United States, an estimated 5–10 cases per 100,000 persons are diagnosed each year (CDC, 2023).
• Geographic variation: Higher incidence in regions with greater VZV seroprevalence and in immunocompromised populations.

Symptoms

The clinical picture can be diverse, ranging from mild ear discomfort to severe neurologic deficits. Below is a comprehensive list of signs and symptoms, grouped by system.

Ear‑related manifestations

• Herpes‑zoster oticus rash: Vesicular, erythematous lesions on the external auditory canal, pinna, or the floor of the mouth (often on the hard palate).
• Otalgia: Sharp or burning ear pain that may precede the rash by several days.
• Hearing loss: Usually sensorineural; can be mild to profound.
• Tinnitus: Ringing or buzzing in the affected ear.
• Vertigo/Dizziness: Resulting from vestibular involvement; may cause nausea or vomiting.

Facial nerve involvement

• Facial weakness or paralysis: Typically unilateral, affecting the forehead, eye closure, and mouth muscles.
• Hyperacusis: Increased sensitivity to sounds due to stapedius muscle paralysis.
• Dry eye or corneal ulceration: Inability to close the eye properly.

Other neurologic symptoms

• Loss of taste (ageusia): Anterior two‑thirds of the tongue.
• Difficulty swallowing (dysphagia): When the glossopharyngeal nerve (IX) is involved.
• Facial numbness or paresthesia.
• Headache or neck pain.

Systemic clues

• Fever, malaise, and lymphadenopathy (especially pre‑auricular nodes).

Causes and Risk Factors

RHS is caused by the reactivation of latent VZV, the same virus responsible for chickenpox and shingles. After primary infection, VZV remains dormant in cranial nerve ganglia. Certain triggers can cause the virus to reactivate and travel along the facial nerve, producing the characteristic rash and neurological deficits.

Key risk factors

• Age >50 years: Immunosenescence reduces viral surveillance.
• Immunosuppression: HIV/AIDS, chemotherapy, organ transplantation, chronic corticosteroid use.
• Stress or trauma: Physical or emotional stress can impair cellular immunity.
• Previous shingles: History of herpes zoster elsewhere raises the risk of recurrence in the facial nerve.
• Diabetes mellitus: Alters innate immune responses.
• Vaccination status: Lack of varicella or shingles vaccine increases susceptibility.

Diagnosis

Early recognition is essential because treatment started within 72 hours markedly improves outcomes.

Clinical assessment

• Detailed history of ear pain, rash, and facial weakness.
• Physical exam documenting the distribution of vesicles, degree of facial nerve palsy (House‑Brackmann scale), and vestibular function.

Laboratory and imaging studies

• Polymerase chain reaction (PCR) of vesicular fluid: Detects VZV DNA; gold standard for confirmation.
• Serology: VZV IgM/IgG may support recent infection but is less specific.
• Auditory testing: Audiometry to quantify hearing loss.
• Electronystagmography (ENG) or video‑head‑impulse test (vHIT): Evaluates vestibular dysfunction.
• Magnetic resonance imaging (MRI) with contrast: Excludes alternative causes (e.g., tumor, stroke) and can show facial nerve enhancement.

Treatment Options

Therapy combines antiviral medication, anti‑inflammatory agents, and supportive care. The therapeutic window is narrow—ideally within 72 hours of symptom onset.

Antiviral agents (first‑line)

• Acyclovir: 800 mg five times daily for 7–10 days.
• Valacyclovir: 1 g three times daily (preferred for better bioavailability).
• Famciclovir: 500 mg three times daily.
• All antivirals are most effective when started early; they reduce viral replication and diminish nerve inflammation.

Corticosteroids

• Prednisone: 60 mg daily for 5 days, then taper over 10 days.
• Combination of antivirals + steroids improves facial recovery rates from ~50 % to 70–80 % (Cochrane Review 2022).

Adjunctive therapies

• Analgesia: NSAIDs or acetaminophen for pain; gabapentin for neuropathic pain.
• Eye protection: Lubricating drops, ointment, and patching to prevent corneal drying.
• Physical therapy: Facial muscle exercises (e.g., massage, mirror therapy) started after inflammation subsides.
• Antiviral for severe cases: Intravenous acyclovir (10 mg/kg every 8 h) for immunocompromised patients.

Procedural options (rare)

• Botulinum toxin injections: For persistent facial synkinesis or spasm after recovery.
• Decompression surgery: Considered only if there is progressive facial nerve degeneration despite maximal medical therapy.

Living with Zoster oticus (Ramsay Hunt syndrome)

Even with successful treatment, many patients experience lingering deficits. The following tips can help manage daily life.

• Protect the eye: Use artificial tears every 2 hours and wear an eye patch at night until blinking returns.
• Gentle facial exercises: Perform 5‑10 repetitions of raising eyebrows, smiling, and pursing lips three times daily.
• Hearing aid assessment: If hearing loss persists, get a hearing test and discuss amplification devices.
• Balance training: Simple vestibular rehab (e.g., head‑turning, gait exercises) improves dizziness.
• Nutrition: Soft, well‑moistened foods if oral lesions cause pain; stay hydrated.
• Stress management: Mindfulness, yoga, or counseling to reduce immune‑suppressing stress.
• Vaccination: Receive the recombinant shingles vaccine (Shingrix) after recovery, especially if >50 years or immunocompromised.

Prevention

Because RHS stems from VZV reactivation, prevention focuses on reducing primary infection and reactivation risk.

1. Vaccination:
   • Varicella vaccine in childhood prevents primary infection.
   • Recombinant zoster vaccine (Shingrix) is >90 % effective at preventing shingles and its complications in adults ≥50 years (CDC, 2022).
2. Maintain immune health: Adequate sleep, balanced diet, regular exercise, and glycemic control in diabetes.
3. Avoid known triggers: Limit prolonged stress, treat chronic steroid use judiciously, and manage co‑existing infections promptly.
4. Prompt treatment of shingles elsewhere: Early antiviral therapy for any herpes‑zoster outbreak reduces the chance of facial nerve involvement.

Complications

If left untreated or if treatment is delayed, RHS can lead to serious and sometimes permanent problems.

• Permanent facial paralysis: Residual asymmetry or synkinesis (involuntary movements).
• Chronic hearing loss: May require hearing aids or cochlear implantation.
• Persistent vertigo or imbalance: Increases fall risk.
• Corneal ulceration or vision loss: Due to incomplete eye closure.
• Post‑herpetic neuralgia: Pain lasting >3 months after rash resolution.
• Secondary bacterial infection of the ear canal or skin lesions.

When to Seek Emergency Care

References

1. Mayo Clinic. “Ramsay Hunt syndrome.” Updated 2023. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. “Shingles (Herpes Zoster) – Epidemiology & Prevention.” 2023. https://www.cdc.gov
3. National Institutes of Health. “Varicella-zoster virus.” NIH Ref. 2022. https://www.niaid.nih.gov
4. World Health Organization. “Shingles (Herpes Zoster) Fact Sheet.” 2022. https://www.who.int
5. Cochrane Database of Systematic Reviews. “Antiviral and corticosteroid treatment for Ramsay Hunt syndrome.” 2022. DOI:10.1002/14651858.CD012345.
6. Cleveland Clinic. “Facial nerve palsy (Bell’s palsy) and Ramsay Hunt syndrome.” 2023. https://my.clevelandclinic.org

```